Eriotinib for advanced hepatocellular carcinoma: A systematic review of phase II/III clinical trials

Objectives: To evaluate the efficacy and safety of eriotinib for the treatment of advanced hepatocellular carcinoma (HCC). Methods: A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was...

Full description

Saved in:
Bibliographic Details
Published in:Saudi medical journal 2016-11, Vol.37 (11), p.1184
Main Authors: Zhang, Jing, Zong, Yuan, Xu, Gang-Zhu, Xing, Ke
Format: Article
Language:English
Subjects:
Aspartate
Cancer treatment
Clinical trials
Hepatocellular carcinoma
Medical schools
Product development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To evaluate the efficacy and safety of eriotinib for the treatment of advanced hepatocellular carcinoma (HCC). Methods: A systematic literature search was undertaken in June 2015. Phase II/III trials of erlotinib for the treatment of advanced HCC were included. A descriptive analysis was applied. The study was conducted in College of Medicine, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China, between June 2015 and January 2016. Results: Ten trials, comprising 9 phase II and one phase III trial, were included in the systematic review. The tumor response rate was 0% in 4 of the phase II trials, 20% in 2 of the phase II trials. The disease control rate was 42.5-79.6% in most studies. Three studies reported a median progression-free survival (PFS) of 6.5-9.0 months, although PFS was
ISSN:0379-5284
DOI:10.15537/smj.2016.11.16267